JPMorgan Chase & Co. reiterated their overweight rating on shares of Spire Healthcare Group (LON:SPI – Free Report) in a research note issued to investors on Thursday morning, MarketBeat Ratings reports. They currently have a GBX 344 ($4.28) price objective on the stock.
Separately, Berenberg Bank upped their price objective on Spire Healthcare Group from GBX 286 ($3.56) to GBX 300 ($3.73) and gave the stock a buy rating in a research note on Wednesday.
View Our Latest Stock Report on Spire Healthcare Group
Spire Healthcare Group Trading Up 0.4 %
Spire Healthcare Group Increases Dividend
The firm also recently declared a dividend, which will be paid on Friday, June 21st. Shareholders of record on Thursday, May 23rd will be paid a GBX 2.10 ($0.03) dividend. This represents a yield of 0.89%. The ex-dividend date of this dividend is Thursday, May 23rd. This is a positive change from Spire Healthcare Group’s previous dividend of $0.50. Spire Healthcare Group’s dividend payout ratio is presently 4,285.71%.
Spire Healthcare Group Company Profile
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.
Read More
- Five stocks we like better than Spire Healthcare Group
- What is the Nikkei 225 index?
- Comprehensive PepsiCo Stock Analysis
- Low PE Growth Stocks: Unlocking Investment Opportunities
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- The Role Economic Reports Play in a Successful Investment Strategy
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Spire Healthcare Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spire Healthcare Group and related companies with MarketBeat.com's FREE daily email newsletter.